Skip to content

Public FDA record

Z-1097-2014: The SYMBIONIC LEG is an integrated prosthetic leg for transfemoral and knee disarticulation amputees.

Recall record Z-1097-2014 for Ossur Americas, Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1097-2014
Company in FDA record
Ossur Americas, Inc.
FDA classification date
Feb 26, 2014
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

OSSUR is recalling the Symbionic Leg because it is not recognizing the low battery warning signal from the Symbionic Leg before it powers down.

Source facts

Action
Ossur Americas contacted all affected customers via phone on October 15, 2012 informing them that a software update for this product is required, along with the recommended instructions to return the product. A loaner prosthetic will be provided to the patient while the software update is being implemented.
Initiated
2012-10-15
Root cause
Other
Terminated
2014-02-28
Distribution
US Nationwide distribution.
Recall number
Z-1097-2014
Recall status
Terminated
CDRH record ID
125090
FDA classified
2014-02-26
Recall event number
67250

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗